Kyverna Therapeutics Inc. will make its trading debut on the Nasdaq Global Market, under the ticker symbol, "KYTX" today, Feb.8, 2024.
This clinical-stage biopharmaceutical company is developing cell therapies for patients suffering from autoimmune diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com